A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma

Abstract Background Combination checkpoint inhibition therapy with yttrium-90 (Y90) radioembolization represents an emerging area of interest in the treatment of advanced hepatocellular carcinoma (HCC). HCRN GI15-225 is an open-label, single-arm multicenter, pilot study (NCT03099564). Methods Eligib...

Celý popis

Podrobná bibliografie

Vydáno v:	The oncologist (Dayton, Ohio) Ročník 29; číslo 3; s. 270 - e413
Hlavní autoři:	Yu, Shawn, Yu, Menggang, Keane, Barry, Mauro, David M, Helft, Paul R, Harris, William P, Sanoff, Hanna K, Johnson, Matthew S, O’Neil, Bert, McRee, Autumn Jackson, Somasundaram, Ashwin
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	US Oxford University Press 01.03.2024
Témata:	Care and treatment Clinical Trial Results Combined modality therapy Hepatoma Liver cancer Medical prognosis Methods Pilot projects Radiotherapy United States pembrolizumab glass Y90 radioembolization hepatocellular carcinoma immunotherapy TARE
ISSN:	1083-7159, 1549-490X, 1549-490X
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!